HIMS Stock Risk & Deep Value Analysis
Hims & Hers Health Inc
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About HIMS Stock
We analyzed Hims & Hers Health Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran HIMS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
HIMS Risk Analysis & Red Flags
What Could Go Wrong
The significant GAAP net loss of -$92 million in Q1 2026, combined with declining gross and adjusted EBITDA margins, indicates that the strategic pivot and international expansion are severely impacting short-term profitability. If the company fails to quickly monetize the Eucalyptus acquisition and new chronic care offerings (especially GLP-1s) to offset the -8% YoY decline in US core revenue, it risks sustained unprofitability and increased cash burn, diminishing its ability to fund future growth.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
High
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Declining US Revenue: -8% YoY in Q1 2026, signaling pressure on the core domestic business.
- ⚠
Significant GAAP Net Loss: -$92 million in Q1 2026, a substantial reversal from Q1 2025's profit.
- ⚠
Gross Margin Compression: Declined to 65% in Q1 2026 from 73% in Q1 2025.
- ⚠
Analyst Consensus: 'Hold' rating with an average target price of $26.61, implying limited immediate upside from the current price ($26.82).
Upcoming Risk Events
- 📅
Intensified US Telehealth Competition (Ongoing): Sustained YoY decline in US core revenue exceeding 10% for two consecutive quarters, indicating significant loss of market share or pricing power.
- 📅
Increased Regulatory Scrutiny on GLP-1 Prescribing (Ongoing): New regulations or enforcement actions from FDA/FTC in Q4 2026 or H1 2027 concerning telehealth prescription of GLP-1 medications, leading to operational restrictions or significant fines.
When to Reconsider
- 🚪
Exit if US revenue decline accelerates to greater than -15% YoY for two consecutive quarters.
- 🚪
Sell if Free Cash Flow turns negative for two consecutive quarters without clear path to recovery.
- 🚪
Exit if Gross Margin falls below 60% and shows no signs of stabilization or improvement.
Unlock HIMS Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Hims & Hers Health Inc (HIMS) Do?
Market Cap
$6.21B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,637
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. The company also provides Labs which measures key markers over time and provides doctor-developed action plans. Hims & Hers Health, Inc. is based in San Francisco, California.
Visit Hims & Hers Health Inc WebsiteInvestment Thesis
If Hims & Hers successfully scales its GLP-1 and chronic care offerings, particularly through the rapidly expanding international footprint from the Eucalyptus acquisition (contributing over 20% of total revenue by H1 2027), and simultaneously stabilizes its US core business (reducing YoY decline to <5%), it could drive total revenue towards its 2030 target of $6.5 billion (vs current ~$3.0B FY26 guidance) and achieve significant Adjusted EBITDA margins of 20% (vs Q1 2026 7%), leading to a substantial re-rating of its valuation multiple as profitability improves. This is bullish because the market is currently under-pricing the long-term potential due to short-term profitability pressures and US core business weakness.
Is HIMS Stock Undervalued?
Unlock the full AI analysis for HIMS
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
HIMS Price Targets & Strategy
12-Month Target
$38.50
Bull Case
$60.00
Bear Case
$18.00
Valuation Basis
3.5x P/S multiple applied to projected FY2026 revenue of $3.0B and 231.5M estimated shares outstanding.
Entry Strategy
Dollar-cost average between $24.00-$26.50, seeking entry below the current analyst consensus target of $26.61.
Exit Strategy
Consider taking initial profits between $38.00-$42.00. Set a stop-loss order at $22.00, below the director's RSU grant price.
Portfolio Allocation
5% for moderate risk tolerance
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is HIMS Financially Healthy?
Valuation
P/E Ratio
48.36
Profitability
Gross Margin
72.92%
Operating Margin
-1.29%
Net Margin
-0.56%
Return on Equity
-2.48%
Revenue Growth
32.81%
EPS
$-0.10
Balance Sheet
Current Ratio
1.90
Quick Ratio
1.61
Debt/Equity
1.80
Other
Beta (Volatility)
2.45
Does HIMS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
4 Identified
The moat is expanding through increased geographic reach via acquisitions like Eucalyptus and an expanding suite of specialized, personalized care offerings, which can build stronger customer relationships. However, the overall telehealth market faces intense competition, relatively low switching costs, and ease of entry for new digital health players, limiting the inherent durability of the moat.
Moat Erosion Risks
- •Commoditization of basic telehealth services, leading to pricing pressure and margin erosion.
- •Aggressive entry of large pharmaceutical companies or tech giants into the GLP-1 or chronic care telehealth space.
- •New regulations that fragment the market or disadvantage existing direct-to-consumer models.
HIMS Competitive Moat Analysis
Sign up to see competitive advantages
HIMS Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to slightly Bullish, driven by excitement around GLP-1 and international growth, but tempered by profitability concerns.
Institutional Sentiment
Neutral, as evidenced by a 'Hold' consensus rating from 16 analysts and an average target price below the current market price.
Insider Activity (Form 4)
Director David B. Wells received 957 RSUs ($22.98 per unit) on 2026-05-21 as board compensation, replacing cash fees. No CEO or CFO Form 4 purchase/sale activity was identified.
Options Flow
Normal options activity.
Earnings Intelligence
Next Earnings
2026-08-03
Surprise Probability
Medium
Historical Earnings Pattern
Likely rallies on strong revenue beats coupled with improved guidance or margin trends; typically sells off on misses or significant margin compression/profitability concerns.
Key Metrics to Watch
Competitive Position
Top Competitor
TDOC
Market Share Trend
Gaining market share rapidly internationally (969% YoY international revenue growth) but appears to be losing ground in its US core business (-8% YoY US revenue). Overall, subscriber base is expanding (+9% YoY).
Valuation vs Peers
Currently trades at a lower forward P/S multiple compared to high-growth, profitable telehealth peers but potentially at a premium to slower-growth, established players, reflecting its growth potential against current unprofitability.
Competitive Advantages
- •Strong direct-to-consumer brand recognition and marketing prowess.
- •Integrated telehealth platform with affiliated pharmacy network for end-to-end patient experience.
- •Personalized treatment models leveraging proprietary data and algorithms.
- •Broad portfolio addressing diverse health needs (sexual health, hair loss, mental health, weight loss).
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive HIMS Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (estimated 2026-08-03): Look for international revenue exceeding $90M and a moderation of US revenue decline to less than -5% YoY, signaling effective strategic execution.
- •GLP-1 Weight Loss Program Update (Q3 2026): Specific announcement of new patient enrollment milestones (e.g., 500,000+ new personalized subscribers) or expansion of treatment options, indicating accelerated growth in a key vertical.
Medium-Term (6-18 months)
- •Eucalyptus Integration & International Scaling (H1 2027): Successful cross-selling across new international markets (Australia, Canada, Germany, Japan, UK) leading to international revenue contributing over 20% of total revenue.
- •Chronic Care Platform Expansion (H2 2027): Launch of additional specialized chronic care programs (e.g., advanced diabetes management or specific neurological conditions) generating an annualized revenue run-rate of over $50 million.
Long-Term (18+ months)
- •Sustained Operating Leverage & GAAP Profitability (FY2028): Achievement of positive GAAP net income and sustained Adjusted EBITDA margin expansion above 10% as subscriber base scales and platform costs are optimized.
- •Global Telehealth Market Leadership (FY2029-2030): Validation of Hims & Hers' 2030 targets of $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA, establishing the company as a top-tier global telehealth provider.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for HIMS?
- ✓
Quarterly International Revenue growth: Must consistently exceed 50% YoY for the next 4-6 quarters to validate international scaling.
- ✓
Gross Margin: Needs to stabilize and begin expanding above 68% by Q4 2026, indicating improved operating efficiency.
- ✓
Personalized Subscriber growth: Must sustain +20% YoY growth, signaling successful GLP-1 and chronic care adoption.
Bull Case Analysis
Sign up free to see the bull case
Competing with HIMS
See how Hims & Hers Health Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Hims & Hers Health Inc HIMS | $6.2B | 7.3 | 48.4 | — | -0.6% | 32.8% | |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Novo Nordisk A/S NVO | $1.3T | 1.3 | 10.6 | $48.6B | 37.2% | 8.1% | Compare → |
Teladoc Health Inc TDOC | $1.4B | 4.3 | 2.0 | $2.5B | -6.8% | -1.5% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Hims & Hers Health Inc Makes Money
Hims & Hers Health Inc. operates as a multi-specialty telehealth platform, providing direct-to-consumer access to licensed healthcare professionals for diagnosis and treatment of various conditions, including sexual health, hair loss, mental health, and increasingly, chronic conditions like weight loss. Patients consult with providers online, and if prescribed medication, it is discreetly dispensed and shipped directly from Hims & Hers' affiliated pharmacies to their homes. The model leverages technology for convenience and affordability, bypassing traditional healthcare hurdles.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Hims & Hers Health Inc (HIMS)?
As of June 15, 2026, Hims & Hers Health Inc has a DVR Score of 7.3 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Hims & Hers Health Inc?
Hims & Hers Health Inc's market capitalization is approximately $6.2B. The company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.
What ticker symbol does Hims & Hers Health Inc use?
HIMS is the ticker symbol for Hims & Hers Health Inc. The company trades on the NYQ.
What is the risk level for HIMS stock?
Our analysis rates Hims & Hers Health Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of HIMS?
Hims & Hers Health Inc currently has a price-to-earnings (P/E) ratio of 48.4. This is above the market average, suggesting the stock may be priced for high growth expectations.
Is Hims & Hers Health Inc's revenue growing?
Hims & Hers Health Inc has reported revenue growth of 32.8%. The company is showing strong top-line momentum.
Is HIMS stock profitable?
Hims & Hers Health Inc has a profit margin of -0.6%. The company is currently unprofitable.
How often is the HIMS DVR analysis updated?
Our AI-powered analysis of Hims & Hers Health Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 15, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for HIMS (Hims & Hers Health Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.